Cyxone files submission to start clinical Phase 2b study in Poland and Georgia
Cyxone (publ), a biotech company in autoimmune diseases, have now filed submissions to the Office for Registration of Medicinal Products, Medical devices and Biocides and the Central Ethics Committee in Poland as well as at local Ethics Committees in Georgia for approval to start a clinical Phase 2b study with its drug candidate Rabeximod, which is being developed as a treatment for rheumatoid arthritis (RA).The submissions to the Regulatory Authorities and the responsible Ethical Committees in Poland and Georgia for approval to start a clinical phase 2b trial with Cyxone’s drug candidate